IceCure Medical Ltd (ICCM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.1700 |
| Open | 1.1300 |
| Bid | 1.1000 x 1000 |
| Ask | 1.1500 x 1100 |
| Day's Range | 1.1200 - 1.1600 |
| 52 Week Range | 0.7500 - 4.7300 |
| Volume | |
| Avg. Volume | 309,814 |
| Market Cap | 52.467M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.03 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ICCM
Related Research
- IceCure Medical Ltd.Daily – Vickers Top Buyers & Sellers for 09/02/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat7 months agoArgus Research
- Insider Monkey
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2022 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2022 Earnings Call Transcript March 29, 2023 Operator: Good morning, and thank you for standing by. . I would now like to turn the conference over to Todd Kehrli. Please go ahead. Todd Kehrli: Thank you, Operator, and welcome to IceCure Medical’s conference call to review the financial results for […]
- PR Newswire
IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023
IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense System of minimally-invasive cryoablation technology that destroys tumors by freezing, today reported audited financial results as of and for the twelve months ended December 31, 2022.
- PR Newswire
IceCure Medical Receives Regulatory Approval in China for Commercial Use of its IceSense3 Disposable Cryoprobes
IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System (marketed under the brand name IceSense3 in China), that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the National Medical Products Administration ("NMPA") of China approved the Company's IceSense3 disposable cryoprobes for commercial use, to be used in combination with the Company's IceSense3 cons
